Filing Flows

Filing Flows › Arrowhead Pharmaceuticals (ARWR) › Next earnings date

Arrowhead Pharmaceuticals (ARWR) earnings on Nov 12, 2026: what to expect

Arrowhead Pharmaceuticals (ARWR) is expected to report earnings on Nov 12, 2026, in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$1.50 (−$3.00 to −$0.35, 15 estimates) on revenue of $60.4M, against −$0.18 and $256M a year ago. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 66% chance of beating next time.

Report dateNov 12, 2026
Days to go4
EPS estimate−$1.50
Revenue estimate$60.4M
Beat rate50%

What to watch

Last quarter (Q3 FY26) the lines that make up revenue grew like this; the report shows whether the trend holds:

Arrowhead Pharmaceuticals: revenue lines, growth year over year, Q3 FY26Arrowhead Pharmaceuticals: revenue lines, growth year over year, Q3 FY26Revenue+171%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.18 on revenue of $374M, against the analysts' −$1.50.

The last report

Arrowhead Pharmaceuticals reported revenue of $75.3M for the third quarter fiscal 2026 (+171% Y/Y), net loss $179M. How it makes money → · Every quarter →

Arrowhead Pharmaceuticals: EPS against the estimate, last 4 reportsArrowhead Pharmaceuticals: EPS against the estimate, last 4 reportsEstimateReported−$0.16−$0.18Nov 25−$0.37$0.22Feb 26−$1.11−$0.93May 26−$1.23−$1.36Aug 26
Latest (Aug 26): Estimate −$1.23, Reported −$1.36.

Arrowhead Pharmaceuticals' latest quarter

Arrowhead Pharmaceuticals, Q3 FY26: revenue $75.3M (+171% year over year), operating margin -226.0%, net loss $179M, operating cash flow −$177M. The chart follows the revenue to costs, profit and cash.

Questions

When does ARWR report earnings?

Arrowhead Pharmaceuticals is expected to report on Nov 12, 2026.

What are analysts expecting from Arrowhead Pharmaceuticals?

EPS of −$1.50 and revenue of $60.4M for the quarter.

Does Arrowhead Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 50% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.